Ursolic Acid
CAS 77-52-1
Ursolic Acid (CAS 77-52-1) is a Phase 2 pharmaceutical compound with 10 bioactivity targets and 0 adverse event associations.
Compound Identity
Matched identifiers and naming fields for the pharmaceutical compound record.
Clinical Development Phase
Highest clinical development phase rendered from the matched compound identifier rows.
Cross-Reference to Cosmetics
Same-CAS ingredient record found in the cosmetics vertical.
Bioactivity & Target Interactions
Target-level activity records with assay counts, activity type, and measured value where present.
| Target | Activity | Value | Assays | Organism |
|---|---|---|---|---|
| - | IC50 | 23735.887100371747 nM | 267 | - |
| - | EC50 | 15264.225 nM | 40 | - |
| - | IC50 | 14.258846153846154 ug.mL-1 | 26 | - |
| - | Potency | 24594.72857142857 nM | 20 | - |
| - | MIC | 89.31818181818181 ug.mL-1 | 11 | - |
| - | Ki | 3255.5555555555557 nM | 9 | - |
| - | MIC | 288960 nM | 5 | - |
| - | EC50 | 1.00205 ug.mL-1 | 2 | - |
| - | GI50 | 16050 nM | 2 | - |
| - | Kd | 46500 nM | 1 | - |
Frequently Asked Questions
Short answers generated only from the same visible source-linked rows on this page.
What is Ursolic Acid used for in pharmaceutical contexts?
Ursolic Acid (CAS 77-52-1) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.
What are the known adverse events for Ursolic Acid?
No adverse-event association or SIDER side-effect rows are rendered for Ursolic Acid in this page query. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.
Is Ursolic Acid also used in cosmetics?
Yes. The ingredients table has a same-CAS cosmetic profile for Ursolic Acid with EU status "permitted".
What clinical phase is Ursolic Acid in?
Ursolic Acid is rendered with ChEMBL max phase 2.